MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1002/jha2.70253

Медицинская библиотека · EJHaem · 2026

Real-World Analysis of Outcomes of Venetoclax+Azacitidine Versus 7+3 Induction in Acute Myeloid Leukemia.

Guevara Rodriguez Nehemias, Mercado Noemy Coreas, Kamal Syeda Ashna Fatima, Beesabathina Sandeep, Foster Dawson, Rajeh Nabeel, Kunwor Ranju

СтатьяПеревод пока не подготовлен

Аннотация

BACKGROUND

Venetoclax plus azacitidine (V+A) is standard for older, intensive-ineligible patients with acute myeloid leukemia (AML). Its expanding use in younger, curative-eligible adults lacks comparative evidence against conventional 7+3 induction, raising uncertainty about potential survival compromise.

METHODS

We performed an age-stratified, retrospective comparative effectiveness study using de-identified TriNetX electronic health records (2018-2025). Adults receiving first-line V+A or 7+3 were propensity-matched 1:1 within prespecified age groups (18-59; ≥60) by demographics, comorbidities, socioeconomic factors, and performance status. The primary endpoint was 1-year all-cause mortality; secondary endpoints included complete remission and ICU admission.

RESULTS

After matching, 214 younger and 1724 older adults per arm were analyzed. Among younger adults, V+A was associated with significantly higher 1-year mortality versus 7+3 (20.6% vs. 8.9%; HR 2.55), with a number needed to harm of nine. Remission rates favored intensive induction (53.3% vs. 44.9%), while ICU use was similar. In older adults, mortality differences were smaller (23.1% vs. 20.5%; HR 1.34; NNH 38), though remission again favored 7+3.

CONCLUSION

V+A appears markedly inferior to 7+3 as first-line therapy in younger, curative-eligible AML, producing a nearly fourfold greater harm signal than in older adults. These findings support restricting V+A to intensive-ineligible patients pending randomized confirmation.

TRIAL REGISTRATION: The authors have confirmed clinical trial registration is not needed for this submission.

Для цитирования: Guevara Rodriguez Nehemias, Mercado Noemy Coreas, Kamal Syeda Ashna Fatima, Beesabathina Sandeep, Foster Dawson, Rajeh Nabeel, Kunwor Ranju. Real-World Analysis of Outcomes of Venetoclax+Azacitidine Versus 7+3 Induction in Acute Myeloid Leukemia.. EJHaem. 2026. DOI: 10.1002/jha2.70253.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.